苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化的临床观察

发布时间：2018-05-13 16:08

本文选题：钙拮抗药 + 血管紧张素转化酶抑制剂　；参考：《中国药房》2017年09期

【摘要】：目的:观察苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化的临床疗效和安全性。方法:90例重度原发性高血压合并颈动脉粥样硬化患者以抽签法分为对照组(45例)和观察组(45例)。两组患者入院后均给予阿托伐他汀钙片20 mg/次,口服,每日1次;同时,对照组患者给予苯磺酸氨氯地平片5 mg/次,口服,每日1次;观察组患者在对照组治疗基础上加服赖诺普利氢氯噻嗪片10 mg/次,口服,每日1次。两组疗程均为8周。比较两组患者临床疗效,治疗前后血压水平、颈动脉内膜中层厚度(IMT)、颈动脉峰值流速(PV)、血清超敏C反应蛋白(hs-CRP)、血浆肿瘤坏死因子α(TNF-α)水平,记录治疗期间不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P0.05);治疗前,两组患者收缩压(SBP)、舒张压(DBP)、IMT、PV、hs-CRP、TNF-α水平比较差异均无统计学意义(P0.05)。治疗后,两组患者SBP、DBP、IMT、PV、hs-CRP、TNF-α水平显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化可有效控制患者血压水平,延缓动脉粥样硬化病情进展,降低机体炎症反应程度,且未增加不良反应的发生,安全性较好。
[Abstract]:Aim: to observe the clinical efficacy and safety of amlodipine benzenesulfonate combined with loproprimahydrochlorothiazide and Atto vastatin in the treatment of severe essential hypertension with carotid atherosclerosis. Methods 90 patients with severe essential hypertension complicated with carotid atherosclerosis were divided into two groups by drawing lots: control group (n = 45) and observation group (n = 45). The patients in both groups were given Atto vastatin calcium tablets once a day for 20 mg/ after admission, while patients in the control group were given amlodipine benzenesulfonic acid tablets for 5 mg/, once a day. The patients in the observation group were treated with liinopril hydrochlorothiazide tablets for 10 mg/, once a day, on the basis of treatment in the control group. The course of treatment was 8 weeks in both groups. The clinical efficacy, blood pressure level, carotid intima-media thickness (IMT), carotid artery peak velocity (PVN), serum hypersensitive C-reactive protein (hs-CRP) and plasma tumor necrosis factor 伪 (TNF- 伪) were compared between the two groups. Results: the total effective rate in the observation group was significantly higher than that in the control group (P 0.05), and there was no significant difference in systolic blood pressure (SBP) and diastolic blood pressure (DBP) between the two groups (P 0.05). After the treatment, the levels of SBPnDBPnI PVHs-CRPN- 伪 in the two groups were significantly lower than those in the same group before treatment, and the levels in the observation group were significantly lower than those in the control group (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: amlodipine benzenesulfonate combined with lysopril hydrochlorothiazide and Atto vastatin can effectively control the blood pressure level and delay the progression of atherosclerosis in patients with severe essential hypertension and carotid atherosclerosis. It is safe to reduce the degree of inflammatory reaction and not increase the occurrence of adverse reactions.
【作者单位】：解放军第255医院药械科;解放军第255医院急诊科;
【分类号】：R544.11

【相似文献】